Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Venetoclax
55%
Survival Prediction
55%
Acute Lymphoblastic Leukemia
55%
Work Disability
55%
Cohort Study
55%
Minimal Residual Disease
55%
Mantle Cell Lymphoma
55%
Case-Control Study
55%
Hodgkin Disease
55%
Diffuse Large B Cell Lymphoma
55%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
55%
Remission
47%
Progression Free Survival
46%
Bruton Tyrosine Kinase Inhibitor
15%
Rituximab
15%
Lenalidomide
15%
Neutropenia
7%
Thrombocytopenia
7%
Acute Leukemia
6%
Comorbidity
6%
Cancer Registry
6%
Hematologic Malignancy
6%
Mortality
6%
Cause Specific Survival
6%
Disease
6%
Malignant Neoplasm
6%
Etoposide
6%
Medicine and Dentistry
Overall Survival
92%
Hodgkin's Lymphoma
55%
Elderly Patient
55%
Acute Lymphoblastic Leukemia
55%
Cohort Analysis
55%
Work Disability
55%
Case-Control Study
55%
Survival Prediction
55%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
55%
Diffuse Large B-Cell Lymphoma
55%
Progression Free Survival
30%
Disability Pension
24%
Population
18%
Attributable Risk
12%
Log Rank Test
12%
Cancer Registry
6%
Mortality
6%
Hematologic Malignancy
6%
Diseases
6%
Cause Specific Survival
6%
Malignant Neoplasm
6%
Pediatrics
6%
Childbirth
6%
Charlson Comorbidity Index
6%
Cumulative Incidence
6%
Acute Leukemia
6%
Etoposide
6%